2F-QMPSB2F-QMPSB (SGT-13)

Formula

C₂₂H₂₀F₂N₂O₄S

Molar mass

446.11 g·mol⁻¹

CAS

-

PubChem CID

155884739

Origin

A wholly synthetic compound with no natural occurrence. It belongs to the illicit market in new psychoactive substances, where it is applied to plant material intended to be smoked, and has never had medical use or pharmaceutical development.

InChIKey

JOSWCKYCXJMLNM-UHFFFAOYSA-N

Editorial estimate, not clinical.

2F-QMPSB belongs to a generation of synthetic cannabinoids designed around a legal objective as much as a chemical one. Most European legislations, including the French one, stopped listing these substances one by one in the mid-2010s and adopted generic definitions by chemical family: indoles, indazoles, pyrroles, indenes, cyclohexylphenols. The sulfamoyl benzoate series escapes that grid by construction, since it contains none of those motifs: the skeleton there is a benzoic ester of 8-hydroxyquinoline bearing a sulfonamide. The compound was identified in plant material seized in Europe in 2018, then notified to the Union's early warning system. Its analytical characterisation, published in 2021 by the Joint Research Centre of the European Commission with the customs laboratory of Milan, mobilised gas chromatography, nuclear magnetic resonance on four nuclei and high-resolution mass spectrometry; the corresponding acid precursor was found in the same sample, an indication of poorly controlled preparation. In vitro metabolism was described in 2023 by Richter and colleagues at Saarland University: hydrolysis of the ester function dominates, catalysed mainly by human type 1 carboxylesterases, and occurs even in the absence of enzyme. What is missing remains the essential: no measurement of affinity or efficacy at cannabinoid receptors is published for this compound, and no human data exist. The class of synthetic agonists is the one whose serious poisonings are best documented in Europe, which makes that absence of characterisation all the more concerning.

An entirely chemical origin, described here by class only. The molecule belongs to the group of synthetic agonists with a sulfamoyl benzoate core: a benzoic acid bearing a methyl and a sulfonyl group linked to a difluorinated piperidine is esterified by 8-hydroxyquinoline. The compound differs from the parent molecule of the series, QMPSB, by the difluorination of the piperidine ring.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

Class

Synthetic cannabinoid (SCRA)

Origin

A wholly synthetic compound with no natural occurrence. It belongs to the illicit market in new psychoactive substances, where it is applied to plant material intended to be smoked, and has never had medical use or pharmaceutical development.

Status

Status changing

1. 1.Tsochatzis et coll. 2021 : identification et caractérisation analytique d'une nouvelle substance de type cannabinoïde de synthèse dans du matériel végétal en EuropePMID 33546439
2. 2.Brandt et coll. 2021 : agonistes synthétiques des récepteurs cannabinoïdes, profils analytiques et développement du QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB et SGT-233PMID 32880103
3. 3.Richter et coll. 2023 : devenir métabolique in vitro du 2F-QMPSB et du SGT-233, cartographie des isozymes et activité des carboxylestérasesPMID 36083120